Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Kepp

Showing results (291-300 of 364) with videos related to

Pageof 37
Sort By:
Journal for Immunotherapy of Cancer|June 15, 2021
IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanismsQi Wu, Ai-Ling Tian, Bei Li, et al.
Plos Pathogens|October 24, 2009
Bacterial porin disrupts mitochondrial membrane potential and sensitizes host cells to apoptosisVera Kozjak-Pavlovic, Elke A Dian-Lothrop, Michael Meinecke, et al.
Cancer Research|February 11, 2010
miR-181a and miR-630 regulate cisplatin-induced cancer cell deathLorenzo Galluzzi, Eugenia Morselli, Ilio Vitale, et al.
Cell Death & Disease|October 12, 2019
Artificial tethering of LC3 or p62 to organelles is not sufficient to trigger autophagyFriedemann Loos, Wei Xie, Valentina Sica, et al.
Cell Cycle (Georgetown, Tex.)|August 12, 2010
Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic deathOliver Kepp, Abdelaziz Gdoura, Isabelle Martins, et al.
The EMBO Journal|January 24, 2009
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell deathTheocharis Panaretakis, Oliver Kepp, Ulf Brockmeier, et al.
Journal for Immunotherapy of Cancer|July 7, 2023
Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responsesShuai Zhang, Liwei Zhao, Mengfei Guo, et al.
The EMBO Journal|February 27, 2010
Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on MosIlio Vitale, Laura Senovilla, Mohamed Jemaà, et al.
Oncoimmunology|June 30, 2023
A Chemically Defined TLR3 Agonist with Anticancer ActivityJulie Le Naour, Sylvain Thierry, Sarah Adriana Scuderi, et al.
EMBO Molecular Medicine|March 23, 2012
Selective killing of p53-deficient cancer cells by SP600125Mohamed Jemaà, Ilio Vitale, Oliver Kepp, et al.
Pageof 37

Showing results (291-300 of 364) with videos related to

Sort By:
Pageof 37
Journal for Immunotherapy of Cancer|June 15, 2021
IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanismsQi Wu, Ai-Ling Tian, Bei Li, et al.
Plos Pathogens|October 24, 2009
Bacterial porin disrupts mitochondrial membrane potential and sensitizes host cells to apoptosisVera Kozjak-Pavlovic, Elke A Dian-Lothrop, Michael Meinecke, et al.
Cancer Research|February 11, 2010
miR-181a and miR-630 regulate cisplatin-induced cancer cell deathLorenzo Galluzzi, Eugenia Morselli, Ilio Vitale, et al.
Cell Death & Disease|October 12, 2019
Artificial tethering of LC3 or p62 to organelles is not sufficient to trigger autophagyFriedemann Loos, Wei Xie, Valentina Sica, et al.
Cell Cycle (Georgetown, Tex.)|August 12, 2010
Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic deathOliver Kepp, Abdelaziz Gdoura, Isabelle Martins, et al.
The EMBO Journal|January 24, 2009
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell deathTheocharis Panaretakis, Oliver Kepp, Ulf Brockmeier, et al.
Journal for Immunotherapy of Cancer|July 7, 2023
Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responsesShuai Zhang, Liwei Zhao, Mengfei Guo, et al.
The EMBO Journal|February 27, 2010
Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on MosIlio Vitale, Laura Senovilla, Mohamed Jemaà, et al.
Oncoimmunology|June 30, 2023
A Chemically Defined TLR3 Agonist with Anticancer ActivityJulie Le Naour, Sylvain Thierry, Sarah Adriana Scuderi, et al.
EMBO Molecular Medicine|March 23, 2012
Selective killing of p53-deficient cancer cells by SP600125Mohamed Jemaà, Ilio Vitale, Oliver Kepp, et al.
Pageof 37